AviadoBio

Biotechnology ResearchEngland, United Kingdom51-200 Employees

AviadoBio is a London-based biotechnology company focused on developing gene therapy-based medicines for neurodegenerative diseases, notably frontotemporal dementia and amyotrophic lateral sclerosis. It seeks to translate advances in brain science into therapies by combining proprietary gene therapy platforms with delivery approaches that aim to reach the central nervous system with precision. The company’s work draws on pioneering research from King’s College London and the UK Dementia Research Institute and adopts a neuroanatomy-led approach to maximize the therapeutic potential of gene therapy.
In 2026, AviadoBio expanded an exclusive license with King’s College London to broaden its neurology-focused platform into a universal IP position covering all human therapeutic areas. This move positions the company to pursue broader applications beyond neurology, while it continues advancing its programs toward clinical testing to help patients affected by FTD and ALS.

Sign up for free to view info

Email Format Employee directory